ProfileGDS5678 / 1425868_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 16% 16% 17% 17% 12% 15% 20% 17% 17% 28% 17% 12% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4115116
GSM967853U87-EV human glioblastoma xenograft - Control 22.4003116
GSM967854U87-EV human glioblastoma xenograft - Control 32.4041316
GSM967855U87-EV human glioblastoma xenograft - Control 42.3664717
GSM967856U87-EV human glioblastoma xenograft - Control 52.3691817
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.3589312
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.3987515
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4633720
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3862617
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.402217
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6290528
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3896917
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.3073412
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4117817